Efficacy and safety of intermittent intravenous doxercalciferol in the treatment of secondary hyperparathyroidism in Chinese patients on maintenance hemodialysis: a phase II, open-label, prospective, multicenter study
Intermittent intravenous doxercalciferol effectively reduces iPTH levels in Chinese MHD patients, with a manageable safety profile. While hypercalcemia is a concern, the incidence of severe cases is not high. This study supports doxercalciferol as a potential treatment option for SHPT in Chinese MHD patients. <b>Clinical Trial Registration:</b> https://www.chictr.org.cn/showproj.html?proj=187332, identifier ChiCTR2300073196.
Authors
- B. Liu (ORCID: https://orcid.org/0009-0005-9003-4937)
- Xiangbao Yu (ORCID: https://orcid.org/0000-0002-8527-2093)
- Tongqiang Liu (ORCID: https://orcid.org/0000-0002-5990-7251)
- Yaoyu Huang
- Huijuan Mao (ORCID: https://orcid.org/0000-0003-4542-6390)
- Xiang Li (ORCID: https://orcid.org/0000-0002-5147-8368)
- Liu L (ORCID: https://orcid.org/0000-0001-9234-457X)
- Chaoqing Gao
- Yifei Ge
- Changhua Liu (ORCID: https://orcid.org/0000-0003-4443-7397)
- Yong Xu
- Wen Li (ORCID: https://orcid.org/0000-0002-3756-4243)
- Guang Yang (ORCID: https://orcid.org/0000-0003-0280-8532)
- Donghua Lou
Institutions
- Xuzhou Medical College (CN)
- Simcere Pharmaceutical (China) (CN)
- Nanjing Traditional Chinese Medicine Hospital (CN)
- The First People's Hospital of Changzhou (CN)
- Second People’s Hospital of Huai’an (CN)
- Northern Jiangsu People's Hospital (CN)
- Changzhou No.2 People's Hospital (CN)
- Jiangsu Province Hospital (CN)
- Third People's Hospital of Hefei (CN)
- First Affiliated Hospital of Wannan Medical College (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-11
- DOI
- https://doi.org/10.3389/fphar.2025.1574679
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Government of Jiangsu Province
- Nanjing Medical University